Laboratorios Farmaceuticos Rovi, S.A. 41L.F

Healthcare · Drug Manufacturers - Specialty & Generic · valued as of 2026-11-03 · statements 2025-12-31

Average Intrinsic Value
$2.84B
Market Cap
$3.41B
Margin of Safety
-20.1%
Intrinsic / Market Ratio
0.83

How Each Value Is Built

The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.

EPV + Growth

3.18B USD

what the normal year's earnings are worth for ever, plus growth that pays

Profit

2.73B USD

15 years of cash the shareholders can take out, and the equity left at year 15

FCFF

2.61B USD

15 years of cash for shareholders and lenders, less what is owed

Intrinsic Value

2.84B USD

the plain average of the three, uncapped, as the screener averages them

Intrinsic Value

2.84B USD

from the sum above

Market Cap

3.41B USD

today's price times the shares

Intrinsic Value ÷ Market Cap

0.83×

the ratio the screener ranks by; Margin of Safety -20.1% (1 − Market Cap ÷ Intrinsic Value)

Each card below builds one of the three values from the reported years.

Earnings power value plus growth: 3.18B USD
What the normal year's operating profit after tax is worth if it lasts for ever, plus what the new investment adds beyond its cost, less the net debt that comes before the shareholders (or plus the net cash).
①EPV (earnings power value)3.01B USD
+②Net Cash Today23.30M USD
+③Growth Value146.13M USD
=Value3.18B USD

EPV of the Operations (NOPAT over WACC)

3.01B USD

Net cash today

+23.30M USD

Growth Value

+146.13M USD

Value

3.18B USD

①EPV (earnings power value)

3.01B USD

②Net Cash Today

23.30M USD

③Growth Value

146.13M USD

Market value

Market Cap3.41B USD

Today's price times the shares.

Value vs market

Margin of Safety-7.1%

1 minus the market cap as a share of the value.

Profit value: today's value of the shareholders' equity, from the cash it can pay them (FCFE): 2.73B USD
Fifteen years of free cash flow to equity (FCFE), each brought to today at the cost of equity, plus the equity at year 15 brought to today.
①Present Value of the 15 Years of FCFE1.80B USD
+②Equity at Year 15, Today935.50M USD
=Value2.73B USD
FCFE: the net income left for the shareholders once the business keeps what next year's growth needsEquity reinvestment: the part of the year's net income kept in the business to grow the next year; below zero, capital the business releases to the shareholdersPresent value of the FCFEColoured bars show the FCFE, grey bars the equity reinvestment. With a positive equity reinvestment the two stacked are the year's normalized income; with a negative one the grey is below zero, capital the business releases, and the normalized income is the FCFE plus that negative amount. Shaded, years 6 to 10: the growth falling to its long-run rate and the ROE on new investment falling to the cost of equity. Axes linear.

①Present Value of the 15 Years of FCFE

1.80B USD

②Equity at Year 15, Today

935.50M USD

Market value

Market Cap3.41B USD

Today's price times the shares.

Value vs market

Margin of Safety-24.8%

1 minus the market cap as a share of the value.

FCFF value: today's value of the shareholders' equity, from the cash the firm can pay its shareholders and lenders (FCFF): 2.61B USD
Fifteen years of free cash flow to the firm (FCFF), each brought to today at the WACC, plus the invested capital at year 15 brought to today, less the net debt today (or plus the net cash).
①Present Value of the 15 Years of FCFF1.72B USD
+②Invested Capital at Year 15, Today857.93M USD
+③Net Cash Today23.30M USD
=Value2.61B USD
FCFF: the NOPAT left for the shareholders and the lenders once the business reinvests what next year's growth needsReinvestment: the part of the year's NOPAT put back into the business to grow the next year; below zero, capital the business releasesPresent value of the FCFFColoured bars show the FCFF, grey bars the reinvestment. With a positive reinvestment the two stacked are the year's NOPAT; with a negative one the grey is below zero, capital the business releases, and the NOPAT is the FCFF plus that negative amount. Shaded, years 6 to 10: the growth falling to its long-run rate and the ROIC on new investment falling to the WACC. Axes linear.

①Present Value of the 15 Years of FCFF

1.72B USD

②Invested Capital at Year 15, Today

857.93M USD

③Net Cash Today

23.30M USD

Market value

Market Cap3.41B USD

Today's price times the shares.

Value vs market

Margin of Safety-30.9%

1 minus the market cap as a share of the value.

The Rates and the Capital the Values Read

The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.

WACC: 5.94%
weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.
Cost of Equity =Risk-Free Rate 4.50%+Beta 0.27×Market Risk Premium 6.00%= 6.09%

The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.

Tax Rate for WACC =Tax Provision 50.45M USDPretax Income 215.50M USD= 23.41%

The tax the interest saves.

Interest Expense =EBIT 218.51M USD−Pretax Income 215.50M USD= 3.02M USD

The interest the company paid: EBIT is the profit before tax plus the interest.

Cost of Debt =Interest Expense 3.02M USDTotal Debt 123.13M USD×(1 − Tax Rate for WACC 23.41%)= 1.88%

What the lenders are paid a year after the tax the interest saves.

Debt Weight =Total Debt 123.13M USDMarket Cap + Total Debt 3.41B USD + 123.13M USD= 3.48%

The part of the capital the lenders put in, at market value.

WACC =Equity Weight 96.52%×Cost of Equity 6.09%+Debt Weight 3.48%×Cost of Debt 1.88%= 5.94%

Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.

Book value and net debt today
Both from the balance sheet of the newest quarter, 2026-06-30.

Total Assets 1.29B USD − Total Liabilities 468.74M USD = Book Value Today 819.84M USD

Total Debt 123.13M USD − Cash and Short-Term Investments 146.43M USD = Net Debt Today -23.30M USD

The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.

Quality metrics
Read beside the value, never a condition for it: every company is valued, and a filter in the list is the reader's choice.
MetricFrom
Share dilutionShares Today ÷ Shares Two Years Back − 1-1.3%at most 5%passes51,142,998 / 51,820,146
Accrual quality(Operating Cash Flow − Net Income) ÷ Total Assets4.3%at least -10.0%passes(219.99M USD − 165.15M USD) ÷ 1.29B USD
Price to bookMarket Cap ÷ Book Value Today4.16×at most 3×does not pass3.41B USD ÷ 819.84M USD
Operating marginOperating Income ÷ Revenue25.0%above 10.0%passes218.46M USD ÷ 874.26M USD
Revenue growthRevenue ÷ Revenue a Year Before − 19.9%above 10.0%does not pass874.26M USD / 795.56M USD
Net cash(Cash − Total Debt) ÷ Market Cap0.6%above -30%passes(145.17M USD − 123.13M USD) ÷ 3.41B USD
Operating efficiencyOperating Income ÷ Gross Profit38.5%above 25.0%passes218.46M USD ÷ 567.59M USD

Market Data

The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.

Market data
The data provider's own ratios and the analysts' consensus, read beside the valuation, never in it.

Share price

60 USD

Enterprise value

2.98B USD

market cap plus net debt

EV / EBITDA

16.91×

Price / book

4.34×

the provider's book

Price / earnings

16.42×

Return on equity

28.6%

the provider's, not the engine's

Profit margin

24.0%

Revenue growth

20.0%

Analyst target, mean

—

Analysts

—

opinions in the consensus

Financial Statements

The income statement, the balance sheet and the cash flow the screener holds, year by year, in USD.

Financial statements, year by year
The annual lines the screener holds today, in USD at each period's rate; the figures this valuation read are in its calculation above.
USD2022202320242025
Income statement

Revenue

872.60M919.03M795.56M874.26M

Gross profit

554.50M545.42M498.27M567.59M

Operating income

273.03M244.03M187.02M218.46M

EBITDA

operating income before depreciation and amortisation

300.34M271.89M216.34M254.23M

Pretax income

275.29M244.20M185.09M215.50M

Net income

213.08M188.72M142.58M165.15M

Normalized income

net income without one-off items, as the data provider prints it; Profit's line when printed

211.57M188.88M142.52M165.69M

R&D

————
Balance sheet, year end

Total assets

937.70M886.21M866.68M1.12B

Total liabilities

381.32M284.06M260.92M329.53M

Shareholders' equity

the equity the parent's shareholders own, as printed, without minority interest; the book value the values read is total assets less total liabilities, in Book Value and Net Debt above

554.93M597.60M595.86M781.29M

Total debt

76.98M72.49M119.18M143.14M

Cash and equivalents

133.33M28.05M28.32M115.21M

Net PP&E

fixed assets after depreciation

230.01M281.03M298.56M388.91M

Working capital

current assets less current liabilities

351.29M342.89M346.82M453.29M
Cash flow

Operating cash flow

253.55M125.47M144.04M219.99M

Capital expenditure

paid out, so below zero

-54.84M-61.14M-64.81M-79.74M

Depreciation and amortisation

24.41M26.96M29.18M35.72M

Free cash flow

operating cash flow plus capital expenditure

198.72M64.33M79.23M140.24M